{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:37:18Z","timestamp":1753882638254,"version":"3.41.2"},"reference-count":107,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["URGENCE COVID-19"],"award-info":[{"award-number":["URGENCE COVID-19"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["2 post-doctoral fellowships"],"award-info":[{"award-number":["2 post-doctoral fellowships"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"name":"EC | Horizon 2020 Framework Programme","award":["101003589 (post-doctoral fellowship)"],"award-info":[{"award-number":["101003589 (post-doctoral fellowship)"]}]},{"DOI":"10.13039\/501100009516","name":"Universit\u00e9 Sorbonne Paris Cit\u00e9","doi-asserted-by":"crossref","award":["doctoral fellowship"],"award-info":[{"award-number":["doctoral fellowship"]}],"id":[{"id":"10.13039\/501100009516","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"crossref","award":["Outbreak Response to Novel Coronavirus (COVID-19): Development of a vaccine against novel coronavirus SARS-CoV-2 using the clinical Phase III measles vector technology"],"award-info":[{"award-number":["Outbreak Response to Novel Coronavirus (COVID-19): Development of a vaccine against novel coronavirus SARS-CoV-2 using the clinical Phase III measles vector technology"]}],"id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2024,5,14]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title\/><jats:p>In the early COVID-19 pandemic with urgent need for countermeasures, we aimed at developing a replicating viral vaccine using the highly efficacious measles vaccine as vector, a promising technology with prior clinical proof of concept. Building on our successful pre-clinical development of a measles virus (MV)-based vaccine candidate against the related SARS-CoV, we evaluated several recombinant MV expressing codon-optimized SARS-CoV-2 spike glycoprotein. Candidate V591 expressing a prefusion-stabilized spike through introduction of two proline residues in HR1 hinge loop, together with deleted S1\/S2 furin cleavage site and additional inactivation of the endoplasmic reticulum retrieval signal, was the most potent in eliciting neutralizing antibodies in mice. After single immunization, V591 induced similar neutralization titers as observed in sera of convalescent patients. The cellular immune response was confirmed to be Th1 skewed. V591 conferred long-lasting protection against SARS-CoV-2 challenge in a murine model with marked decrease in viral RNA load, absence of detectable infectious virus loads, and reduced lesions in the lungs. V591 was furthermore efficacious in an established non-human primate model of disease (see companion article [S. Nambulli, N. Escriou, L. J. Rennick, M. J. Demers, N. L. Tilston-Lunel et al., J Virol 98:e01762-23, 2024,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1128\/jvi.01762-23\" xlink:type=\"simple\">https:\/\/doi.org\/10.1128\/jvi.01762-23<\/jats:ext-link>]). Thus, V591 was taken forward into phase I\/II clinical trials in August 2020. Unexpected low immunogenicity in humans (O. Launay, C. Artaud, M. Lach\u00e2tre, M. Ait-Ahmed, J. Klein et al., eBioMedicine 75:103810, 2022,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103810\" xlink:type=\"simple\">https:\/\/doi.org\/10.1016\/j.ebiom.2021.103810<\/jats:ext-link>) revealed that the underlying mechanisms for resistance or sensitivity to pre-existing anti-measles immunity are not yet understood. Different hypotheses are discussed here, which will be important to investigate for further development of the measles-vectored vaccine platform.<\/jats:p><jats:sec><jats:title>IMPORTANCE<\/jats:title><jats:p>SARS-CoV-2 emerged at the end of 2019 and rapidly spread worldwide causing the COVID-19 pandemic that urgently called for vaccines. We developed a vaccine candidate using the highly efficacious measles vaccine as vector, a technology which has proved highly promising in clinical trials for other pathogens. We report here and in the companion article by Nambulli et al. (J Virol 98:e01762-23, 2024,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1128\/jvi.01762-23\" xlink:type=\"simple\">https:\/\/doi.org\/10.1128\/jvi.01762-23<\/jats:ext-link>) the design, selection, and preclinical efficacy of the V591 vaccine candidate that was moved into clinical development in August 2020, 7 months after the identification of SARS-CoV-2 in Wuhan. These unique in-human trials of a measles vector-based COVID-19 vaccine revealed insufficient immunogenicity, which may be the consequence of previous exposure to the pediatric measles vaccine. The three studies together in mice, primates, and humans provide a unique insight into the measles-vectored vaccine platform, raising potential limitations of surrogate preclinical models and calling for further refinement of the platform.<\/jats:p><\/jats:sec><\/jats:sec>","DOI":"10.1128\/jvi.01693-23","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T15:00:23Z","timestamp":1712070023000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I\/II clinical trials: candidate selection in a preclinical murine model"],"prefix":"10.1128","volume":"98","author":[{"given":"J\u00e9r\u00e9my","family":"Brunet","sequence":"first","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, D\u00e9partement de Sant\u00e9 Globale, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaineb","family":"Choucha","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, D\u00e9partement de Sant\u00e9 Globale, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Gransagne","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, D\u00e9partement de Sant\u00e9 Globale, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houda","family":"Tabbal","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, CNRS UMR3569, G\u00e9n\u00e9tique Mol\u00e9culaire des Virus \u00e0 ARN, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Wen","family":"Ku","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, Pasteur-TheraVectys Joint Lab, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Buchrieser","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, CNRS UMR3569, Virus and Immunity Unit, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, INSERM U1223, Innate Immunity Unit, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Batalie","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, CNRS UMR3569, G\u00e9n\u00e9tique Mol\u00e9culaire des Virus \u00e0 ARN, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodie","family":"Lopez","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, Pasteur-TheraVectys Joint Lab, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Ma","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, Biomics, C2RT, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyne","family":"Dufour","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, CNRS UMR 3528, Production and Purification of Recombinant Proteins Technological Platform, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emeline","family":"Simon","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, CNRS UMR3569, G\u00e9n\u00e9tique Mol\u00e9culaire des Virus \u00e0 ARN, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hardy","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, Histopathology Platform, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Petres","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, CNRS UMR 3528, Production and Purification of Recombinant Proteins Technological Platform, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Guinet","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, INSERM U1223, Lymphocytes and Immunity Unit, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Strick-Marchand","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, INSERM U1223, Innate Immunity Unit, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Monot","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, Biomics, C2RT, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Charneau","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, Pasteur-TheraVectys Joint Lab, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laleh","family":"Majlessi","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, Pasteur-TheraVectys Joint Lab, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1716-6376","authenticated-orcid":true,"given":"W. Paul","family":"Duprex","sequence":"additional","affiliation":[{"name":"Center for Vaccine Research, Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9446-8031","authenticated-orcid":false,"given":"Christiane","family":"Gerke","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, Innovation Office, Vaccine Programs, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3054-3925","authenticated-orcid":false,"given":"Annette","family":"Martin","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, CNRS UMR3569, G\u00e9n\u00e9tique Mol\u00e9culaire des Virus \u00e0 ARN, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-6839","authenticated-orcid":false,"given":"Nicolas","family":"Escriou","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, D\u00e9partement de Sant\u00e9 Globale, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"},{"key":"e_1_3_5_4_2","unstructured":"World Health Organization. 2023. WHO COVID-19 dashboard. Available from: https:\/\/covid19.who.int. Retrieved 27 Jul 2023."},{"key":"e_1_3_5_5_2","unstructured":"World Health Organization. 2023. WHO director-general's opening remarks at the media briefing. Available from: https:\/\/www.who.int\/news-room\/speeches\/item\/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023. Retrieved 27 Jul 2023."},{"key":"e_1_3_5_6_2","unstructured":"BastaNE Moodie EMM on behalf of the VIPER (Vaccines IdP and Epidemiology Research) Group COVID-19 Vaccine Development and Approvals Tracker Team. 2022. COVID-19 vaccine development and approvals tracker. Available from: https:\/\/covid19.trackvaccines.org\/vaccines\/approved\/#vaccine-list. Retrieved 27 Jul 2023."},{"key":"e_1_3_5_7_2","unstructured":"World Health Organization. 2023. COVID-19 vaccines with WHO emergency use listing. Available from: https:\/\/extranet.who.int\/pqweb\/vaccines\/vaccinescovid-19-vaccine-eul-issued. Retrieved 27 Jul 2023."},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-023-00515-2"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4914(03)00133-3"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030781"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1211721"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2014.01.010"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-021-00418-x"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.058"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13010109"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.04.022"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1407087111"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15562-9"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-021-00908-w"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100040"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4250"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01313-z"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3143"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.01.002"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01815-15"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01781"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.809244"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00526-x"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb00266.x"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.6.4823-4828.1999"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.21.11546-11554.2003"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32488-7"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2017.0143"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70043-5"},{"key":"e_1_3_5_38_2","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01762-23","article-title":"A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-Cov-2 spike protein brought to phase I\/II clinical trials: protection of African green monkeys from COVID-19 disease","volume":"98","author":"Nambulli S","year":"2024","unstructured":"Nambulli S, Escriou N, Rennick LJ, Demers MJ, Tilston-Lunel NL, McElroy AK, Barbeau DJ, Crossland NA, Hoehl RM, Schrauf S, White AG, Borish HJ, Tomko JA, Frye LJ, Scanga CA, Flynn JL, Martin A, Gerke C, Hartman AL, Duprex WP. 2024. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-Cov-2 spike protein brought to phase I\/II clinical trials: protection of African green monkeys from COVID-19 disease. J Virol 98:e1762-23. https:\/\/doi.org\/10.1128\/jvi.01762-23.","journal-title":"J Virol"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103811"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103810"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2007.01.012"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243283"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1707304114"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34171-7"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106267"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000494"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2018.08.014"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02648-20"},{"key":"e_1_3_5_49_2","unstructured":"International Coaltion of Medicines Regulatory Authorities. 2020. Summary report: Global regulatory workshop on COVID-19 vaccine development. Available from: https:\/\/www.icmra.info\/drupal\/news\/March2020\/summary. Retrieved 23 Mar 2020."},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035421"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202049058"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2622-0"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033989"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128714"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.12.010"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202187"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.011"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1838955"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2014468117"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.11.6900-6908.2005"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00243-x"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.141.6.1335"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.76.17.8875-8889.2002"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9143"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.04.083"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03275-y"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026785118"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.04.022"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-3035-9"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2607-z"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026153118"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25589-1"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2013.813899"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-007-0071-6"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06048-11"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02980-14"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00087-13"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.06.018"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh3827"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111214"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw3163"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.10.3.411-416.2003"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00447-3"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1562908"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00048-X"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2017.14465"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31605-6"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.05.086"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-82-3-641"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30200-0"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006863"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.67.8.4822-4830.1993"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1996.8339"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2004.09.079"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.21105\/joss.00352"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giy110"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2017.12.007"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpbi.102"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2019"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.9.7420-7427.1998"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.08.033"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a118408"},{"key":"e_1_3_5_104_2","unstructured":"National Institute for Biological Standards and Control. 2020. Data sheet: research reagent for anti-SARS-CoV-2 Ab. NIBSC code 20\/130. Available from: https:\/\/nibsc.org\/documents\/ifu\/20-130.pdf. Retrieved 29 Feb 2024."},{"key":"e_1_3_5_105_2","unstructured":"National Institute for Biological Standards and Control. 2020. Data sheet: COVID-19 convalescent plasma panel human. NIBSC code 20\/118. Available from: https:\/\/nibsc.org\/documents\/ifu\/20-118.pdf. Retrieved 29 Feb 2024."},{"key":"e_1_3_5_106_2","unstructured":"World Health Organization. 2020. WHO\/BS\/2020.2403: establishment of the WHO international standard and reference panel for anti-SARS-CoV-2 antibody. Available from: https:\/\/www.who.int\/publications\/m\/item\/WHO-BS-2020.2403. Retrieved 29 Feb 2024."},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045"},{"key":"e_1_3_5_108_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M401148200"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jvi.01693-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jvi.01693-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T14:04:41Z","timestamp":1731679481000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jvi.01693-23"}},"subtitle":[],"editor":[{"given":"Rebecca Ellis","family":"Dutch","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,14]]}},"alternative-id":["10.1128\/jvi.01693-23"],"URL":"https:\/\/doi.org\/10.1128\/jvi.01693-23","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"type":"print","value":"0022-538X"},{"type":"electronic","value":"1098-5514"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"2023-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01693-23"}}